Luye Pharma Group Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYPHF research report →
Price Chart
About the company
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors.
- CEO
- Dian Bo Liu
- IPO
- 2021
- Employees
- 5,221
- HQ
- Yantai, GD, CN
Get TickerSpark's AI analysis on LYPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.08B
- P/E
- 7.54
- Fwd P/E
- 1.52
- PEG
- 0.14
- P/S
- 0.85
- P/B
- 0.34
- EV/EBITDA
- 4.99
- Div Yield
- 0.00%
- Gross Margin
- 63.75%
- Op Margin
- 18.49%
- Net Margin
- 11.36%
- ROE
- 4.40%
- ROIC
- 2.57%
Latest fiscal year · YoY change
- Revenue
- $6.15B+1.4%
- Gross Profit
- $4.06B+0.3%
- Op Income
- $1.22B
- Net Income
- $602.78M+27.7%
- EPS
- $0.15+757.1%
- OCF Growth
- +962.9%
- FCF Growth
- +150.7%
- 52W High
- $0.40
- 52W Low
- $0.20
- 50D MA
- $0.27
- 200D MA
- $0.30
- Beta
- 0.87
- RSI (14)
- 57
- Avg Volume
- 10.42K
No earnings-call transcripts are available for LYPHF yet.
- Free Float
- 53.4%
- Shares Outstanding
- 3.99B
- Float Shares
- 2.13B
Our LYPHF coverage
Recent articles, reports, and earnings notes.
No research on LYPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LYPHF report →